Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMX-BAR
2023-510404-44-02Phase 3Authorised
- Sponsor
- Helse Bergen
- Start
- Oct 2022
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of diazepam and oxazepam in benzodiazepine dependence and opioid use disorder (OUD) (2 arms), sponsored by Helse Bergen. Primary endpoint: Illegal benzodiazepine use index at week 24 vs baseline. Planned start Oct 2022; status: authorised.
02
Drugs
diazepamoxazepam
03
Conditions
benzodiazepine dependenceopioid use disorder (OUD)
Beyond the preview
Go deeper on 2023-510404-44-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510404-44-02.